The NHS is set to introduce a new once-a-day tablet that targets advanced breast cancer, with around 1,100 patients in ...

Elacestrant, also known as Korserdu and made by Menarini Stemline, is used to treat a specific kind of cancer - oestrogen ...

We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

Targeting the estrogen receptor and HER2 pathways improved progression-free survival in patients with HR-positive, ...

Fred Hutch graduate student Adam Nguyen has won a F31 training award from the NIH to study a complex molecule called Tie2 ...

The Food and Drug Administration has approved Ensacove for patients with ALK-positive locally advanced or metastatic ...

A machine learning tool incorporating both clinical and genomic data helps predict response to CDK4/6 inhibitor therapy in ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

A new once-a-day tablet that treats advanced breast cancer is to be rolled out on the NHS, with about 1,100 patients in ...

Xcovery Holdings, Inc., an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the ...